Tag: PhRMA

PhRMA

General

PhRMA’s Updated Code for Industry Addresses Speaker Programs, Meals

PhRMA’s Updated Code for Industry Addresses Speaker Programs, Meals

Aug. 20, 2021 — The Pharmaceutical Research and Manufacturers of America (PhRMA) has “updated and enhanced” its voluntary code of ethics regarding how the drug industry can appropriately interact with U.S. health care professionals (HCPs) while marketing biopharma products in various ways, including speaker programs. PhRMA’s revised “Code on Interactions with Health Care Professionals,” last updated […]

Read more

Legislative

What Biden’s Drug Pricing Plans Could Mean for Biopharma

What Biden’s Drug Pricing Plans Could Mean for Biopharma

Aug. 16, 2021 – As part of his “Build Back Better” agenda, President Joe Biden re-emphasized in a televised address last week that he would like Congress to make changes that would allow Medicare to negotiate drug prices to reduce costs for “millions of Americans.” Specifically, Biden wants to see legislative reforms that would remove […]

Read more

Regulatory/FDA

HHS OIG Releases Fraud Alert on Speakers Bureaus

HHS OIG Releases Fraud Alert on Speakers Bureaus

Nov. 20, 2020 – In a rare special fraud alert issued Nov. 16, the Department of Health and Human Services Office of Inspector General (OIG) expresses skepticism about the value of company-sponsored speaker bureau events, outlines its concerns about “inherent fraud and abuse risks” associated with these programs, and offers a non-exhaustive list of the […]

Read more

Washington Focus

Movement in White House-Pharma Industry Standoff on Drug Pricing?

Movement in White House-Pharma Industry Standoff on Drug Pricing?

Aug. 31, 2020 – Following the Democratic and Republican convention attacks on big pharma and President Trump’s acceptance speech for his party’s nomination for re-election – in which he claimed to have already taken effective action to lower prescription drug prices through Executive Orders  – the Pharmaceutical Research and Manufacturers of America (PhRMA) is making […]

Read more

Washington Focus

Trump Executive Order Calling for U.S. Production of Drugs Raises Eyebrows, Questions

Trump Executive Order Calling for U.S. Production of Drugs Raises Eyebrows, Questions

Aug. 7, 2020 – The Executive Order signed Aug. 6 by President Donald J. Trump  to increase production of essential medical supplies in the United States is raising a lot of eyebrows in the biopharmaceutical industry, largely because pivoting to such a model will not be easy and may end up costing more, both in […]

Read more

Washington Focus

Trump’s Drug Pricing Executive Orders Unlikely to Have Immediate Effect

Trump’s Drug Pricing Executive Orders Unlikely to Have Immediate Effect

July 27, 2020 – The four Executive Orders signed by President Trump on Friday were designed to address drug pricing concerns, but their combined impact is modest and they are “unlikely to have any immediate effect,” according to Coalition for Healthcare Communication Executive Director Jon Bigelow. However, they do “give the president talking points for […]

Read more

DTC Advertising

Despite Industry’s Price Transparency Initiatives, CMS Pushes Proposed Rule Forward

Despite Industry’s Price Transparency Initiatives, CMS Pushes Proposed Rule Forward

April 8, 2019 – The first television ads including drug price information are hitting the airwaves, reinforcing the point that list price is a highly misleading metric, and Pharmaceutical Research and Manufacturers of America (PhRMA) members are preparing to voluntarily refer consumers to online drug pricing information in their drug ads within a few weeks. […]

Read more

DTC Advertising

Oregon Considers Drug Price Disclosures in All Consumer Ads

Oregon Considers Drug Price Disclosures in All Consumer Ads

Feb. 25, 2019 – Even as the Centers for Medicare & Medicaid Services considers comments received on a federal proposal to mandate the inclusion of the wholesale acquisition cost (WAC) of prescription drugs in consumer television ads, the state of Oregon is weighing whether or not to require a disclosure regarding the wholesale cost that […]

Read more

DTC Advertising

Trade Groups Say CMS Lacks Authority to Mandate Drug Prices in DTC TV Ads

Trade Groups Say CMS Lacks Authority to Mandate Drug Prices in DTC TV Ads

Jan. 15, 2019 – In comments to the Centers for Medicare and Medicaid Services (CMS) regarding its proposal to require that drug companies include the wholesale acquisition cost (WAC) of a drug in direct-to-consumer (DTC) television ads, industry trade groups and pharmaceutical companies largely are in agreement that doing so would confuse consumers, that CMS […]

Read more

Washington Focus

PhRMA’s Zirkelbach: New DTC Code Provides Information Consumers Really Want on Coverage

PhRMA’s Zirkelbach: New DTC Code Provides Information Consumers Really Want on Coverage

Dec. 10, 2018 – The Health and Human Services (HHS) proposal to require that drug companies include drug list prices in direct-to-consumer (DTC) ads could potentially confuse patients, and it also could cause patients to defer treatment because of the misleading price tag, according to Robert Zirkelbach, EVP of public affairs, Pharmaceutical Research and Manufacturers […]

Read more